India Globalization Capital announces it has received a no objection letter from Health Canada for approval of its trial, "A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial of the Safety and Efficacy of IGC-AD1 on Agitation in Participants with Dementia due to Alzheimer’s Disease." The no objection letter provides the acknowledgement of IGC-AD1’s drug candidacy and the authority to proceed with Phase 2 trials in Canada.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on IGC:
- FDA explores regulating CBD in foods, supplements, WSJ reports
- Rising High: Exclusive talk with staffing firm CannabizTeam
- India Globalization Capital announces updated life sciences presentation
- IGC Announces Updated Life Sciences Presentation
- Rising High: Exclusive talk with market research firm Brightfield Group
